Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734926 | 1.00 | PTPN1 (0.47) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26015705 | 0.93 | TLR2 (0.46) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL13225452 | 0.92 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL13696901 | 0.92 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL15674187 | 0.91 | PTPN1 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL17807593 | 0.91 | MDM2 (0.45) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL23253718 | 0.89 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL26015648 | 0.89 | PTPN1 (0.44) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286080 | 0.88 | PTPN1 (0.45) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL16450347 | 0.88 | PTPN1 (0.48) | PTPN1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466260-B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-7851437-B2 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7829531-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | SEATTLE GENETICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062008-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | PTPN1 3157/4885SIRT2 2395/4885SIRT1 1843/4885 |
| US-20100260748-A1 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | FCGR3B, FCGRT, FCGR1A | PTPN1 1017/4885SIRT2 4756/4885SIRT1 4874/4885 |
| US-20090324621-A1 | monoclonal antibody conjugated with peptide drug such as dolastatin derivative | DAD1, DDOST, STT3A | PTPN1 3157/4885SIRT2 2395/4885SIRT1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.